Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
79 Brain Function Trials Near You
Power is an online platform that helps thousands of Brain Function patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerBrain Training for Young Children
New York, New York
Koronis Biomedical Technologies Corporation (KBT) is developing a cognitive intervention to promote healthy development of Executive Function (EF) skills in young children by leveraging a smartphone-based training regime designed for parents.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:2 - 5
Key Eligibility Criteria
Disqualifiers:Physical Disabilities, Severe Developmental Delays, Others
140 Participants Needed
fMRI for Brain Cancer
New York, New York
The purpose of this study is to test the accuracy of using an imaging technique called breath-holding functional magnetic resonance imaging (BH fMRI) in addition to the standard imaging test described above. This study will allow the researchers to find out whether using BH fMRI in combination with the standard approach is the same as, better, or worse than the standard approach used alone.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Neurological, Psychiatric, Cancer, Others
33 Participants Needed
Vancomycin for Multiple Sclerosis
New York, New York
This trial is testing vancomycin, an antibiotic, to see if it can change gut bacteria and help reduce brain inflammation in people with multiple sclerosis (MS). The goal is to understand if altering gut bacteria can improve immune function and lessen MS symptoms.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 50
Key Eligibility Criteria
Disqualifiers:Pregnancy, Diabetes, HIV, Others
Must Not Be Taking:Antibiotics, Corticosteroids, Immunosuppressants, Others
12 Participants Needed
Stem Cells + Light Therapy for Alzheimer's Disease and Autism
Westport, Connecticut
The purpose of the study is to evaluate the use of autologous Bone Marrow Derived Stem Cells (BMSC) as a means to improve cognitive impairment as occurs in Alzheimer's Disease and other dementias and to improve behavior and socialization issues which occur in adult Autism Spectrum Disorder. The use of Near Infrared Light, in conjunction with the use of BMSC, will also be assessed.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Unstable Health, Pregnancy, Others
100 Participants Needed
Cognitive Remediation for Cognitive Impairment
Ottawa, Ontario
Forensic patients often display cognitive deficits, particularly in the domain of executive functions, that represent a challenge to forensic rehabilitation.
One empirically-validated method to train executive functions is cognitive remediation, which consists of cognitive exercises combined with coaching.
This trial investigates whether cognitive remediation can improve cognitive, functional, and clinical outcomes in forensic inpatients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:Not Listed
30 Participants Needed
Contrave for Obesity
Ottawa, Ontario
Obesity is a common chronic disease linked with increased risk for other illnesses and earlier death. Our team and others have shown that many bodily and psychological changes occur when individuals are on calorie-restricted diets. These changes might undermine dietary adherence and help to explain the relatively poor long-term efficacy of diets. These include increased appetite, increased food 'value' and 'wanting' that leads to overconsumption. Other factors include more sensitive sensory cues (e.g., smelling), higher food liking and craving, and a drop in resting energy expenditure (REE). REE has been shown to predict weight regain.
The standard care for obesity may include the use of the weight-loss drug CONTRAVE®. The Federal Drug Agency (FDA) and Health Canada have approved this drug for weight management and obesity treatment.
Although CONTRAVE® was designed to reduce appetite, food-related impulsivity and cravings, its mechanisms of action are unclear. In other words, the effects of CONTRAVE® on REE, executive function, and brain changes remain unknown in humans. A better understanding of how this drug works on the brain and body could lead to improvements in obesity management in the future.
As such, the goal of this research is to study the effects of 4 weeks of CONTRAVE® (+ diet program) vs. control (placebo pill + diet program) on mood, body composition changes, biological/metabolic measures, and brain measures.
Adults aged 18-64 with obesity will be randomized to one of two groups: diet + CONTRAVE® (CONTRAVE®, 20 participants) or diet + Placebo (Placebo, 20 participants). Both groups will be assigned the same study procedures for the entire study duration. The only difference is that Group 1 will receive CONTRAVE® while Group 2 will receive a placebo (non-medical) pill.
The study design and intervention is as follows:
Participants who meet all the telephone screening criteria will be invited to the Clinical EEG \& Neuroimaging Laboratory at The Royal's IMHR for an in-person screening and test-dose session. Participants who are cleared by the study physician, Dr. Pierre Blier, during the in-person screening will be enrolled in the 4-weeks trial.
After the in-person screening visit, participants will attend two baseline testing visits (before starting the medication + diet program). The first will occur at the Behavioural and Metabolic Research Unit at the University of Ottawa. During this in-person visit, measures of body composition, resting energy expenditure, appetite, food craving, impulsivity, eating behaviours, taste and odour sensitivity, energy intake, and food preference will be collected.
The second baseline visit (within a week of the first one) will occur at The Royal/IMHR. During this visit, participants will be asked to complete questionnaires. They will undergo an EEG recording while resting and performing computer tasks. They will also get a brain imaging scan, during which they are asked to rest and complete a computer task.
Both testing sessions (University of Ottawa and Royal Ottawa testing sessions) will be repeated after four weeks of treatment. The section below provides further description and timing of these visits.
As part of the treatment, you will receive an individualized dietary intervention with appropriate energy restriction from a registered dietitian at Dr. Judy Shiau's LEAF weight management clinic (called the 4-week BUDS program). The program involves weekly touch points with a registered dietitian and meal planning/coaching. The diet intervention will commence the same week as the start of the placebo/CONTRAVE®.
During the 4-week intervention, participants will be asked to complete online questionnaires at various times.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 64
Key Eligibility Criteria
Disqualifiers:Severe Depression, Diabetes, Cardiac Defects, Others
Must Be Taking:Contrave
40 Participants Needed
Synaquell™ for Brain Health in Athletes
Rochester, Minnesota
This research is being done to investigate the dietary supplement, Synaquell (TM), for effects on brain function in youth contact sport athletes.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:13 - 19
Key Eligibility Criteria
Disqualifiers:Hearing Issues, Seizures, Pregnancy, Others
40 Participants Needed
The ACTIONcardioRisk trial is designed to investigate the effect of aerobic and progressive resistance training exercises combined with cognitive training, on neurocognitive functioning of sedentary older adults with and without cardiovascular risk factors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:60+
Key Eligibility Criteria
Disqualifiers:Dementia, Neurological Disease, Heart Failure, Others
159 Participants Needed
Cognitive & Physical Exercise for Heart Failure
Montreal, Quebec
The objective of this project is to assess the effects of combined physical exercise and cognitive training interventions on cognitive and brain health in patients with heart failure (HF). Also, the role of sex on the effects of the interventions will be assessed.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:60+
Key Eligibility Criteria
Disqualifiers:Acute Cardiovascular Event, Severe Exercise Intolerance, Severe Respiratory Disease, Uncontrolled Diabetes, Others
Must Be Taking:ACE-I, ARBs, MRA
216 Participants Needed
Transcranial Magnetic Stimulation for Concussion
Saint Paul, Minnesota
Persistent post-concussive symptoms (PPCS) involve an array of physical, cognitive, and behavioral symptoms lasting more than a month after mild traumatic brain injury (mTBI). 34-44% of people with mTBI or concussion present with a considerable burden of PPCS 3-6 months after injury. There is currently no standardized treatment for PPCS, nor FDA approved medication for any neuropsychiatric or neurocognitive symptoms associated with mTBI. Transcranial magnetic stimulation (TMS) shows promise as a treatment for PPCS; however, the current one-size-fits-all approach does not address the heterogeneity of symptoms. We propose utilization of resting state functional MRI (rs-fMRI) guided rTMS to target personalized brain networks burdened with PPCS.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Seizure Disorder, Substance Use, Others
20 Participants Needed
Non-invasive Brain Stimulation for Dementia
Boston, Massachusetts
This trial tests a home-based brain stimulation treatment using gentle electrical currents to improve memory, movement, and thinking skills in older adults with early-stage memory problems. Caregivers are trained to administer the treatment at home. This method has been widely studied for its potential to enhance cognitive function in older adults, including those with neurodegenerative diseases like Alzheimer's.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:55+
Key Eligibility Criteria
Disqualifiers:Major Psychiatric Disorders, Seizures, Others
Must Not Be Taking:Neuroactive Drugs
144 Participants Needed
Transcranial Direct Current Stimulation for Dementia
Roslindale, Massachusetts
The objective of this study is to determine the effects of a 6-month, home-based personalized transcranial direct current stimulation (tDCS) intervention targeting the left dorsolateral prefrontal cortex on cognitive function, dual task standing and walking, and other metrics of mobility in older adults with motoric cognitive risk syndrome (MCR).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:65 - 90
Key Eligibility Criteria
Disqualifiers:Dementia, Major Psychiatric Disorder, Seizures, Others
128 Participants Needed
Electrical Stimulation for Depression
Boston, Massachusetts
In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric populations known to have deficits in this cognitive domain.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Epilepsy, Metallic Implants, Pregnancy, Others
Must Not Be Taking:Psychotropic Medications
600 Participants Needed
Meditation for Brain Health
Boston, Massachusetts
This trial will test if a 21-minute meditation called Shambhavi Mahamudra Kriya can improve brain health and overall well-being. The study targets people interested in better brain function and reduced stress. The meditation uses specific breathing and meditation techniques to help achieve these benefits. Shambhavi Mahamudra Kriya is a multicomponent breath-based yogic practice that has been shown to reduce perceived stress and improve general well-being after regular practice.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:20 - 65
Key Eligibility Criteria
Disqualifiers:Severe Anxiety, Depression, Schizophrenia, Others
Must Not Be Taking:Cognition Enhancers
80 Participants Needed
Vagus Nerve Stimulation for Alzheimer's Disease
Boston, Massachusetts
This study will determine how noninvasive nerve stimulation affects human brain, stomach, and autonomic activity.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:FmrI Contraindications, Others
50 Participants Needed
Individualized TMS for Depression
Boston, Massachusetts
This trial tests aiTBS, a magnetic brain stimulation method, on patients with depression that hasn't responded to other treatments. The treatment uses magnetic pulses to reset brain activity and improve mood. Participants will receive aiTBS either guided by brain scans or by physical measurements of the head. Intermittent Theta Burst Stimulation (iTBS) is a newer form of repetitive Transcranial Magnetic Stimulation (rTMS) that has shown potential for faster and more intense effects in treating depression.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:22 - 80
Key Eligibility Criteria
Disqualifiers:Pregnancy, ECT Non-response, Neurological Illness, Others
Must Be Taking:Antidepressants
40 Participants Needed
Ketogenic Diet for Type 1 Diabetes
Boston, Massachusetts
This trial tests if a special low-carb diet or a ketone drink can help people with type 1 diabetes manage low blood sugar and improve brain function. The diet makes the body produce ketones, which the brain can use for energy when blood sugar is low. Researchers will compare brain activity during low blood sugar episodes in participants following the diet versus those who are not. The low-carbohydrate, ketogenic diet (LCKD) has been studied for its potential to improve blood sugar management and reduce medication use in diabetes care.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 40
Key Eligibility Criteria
Disqualifiers:Ketoacidosis, Severe Hypoglycemia, Others
Must Be Taking:Insulin, Metformin
24 Participants Needed
Transcranial Magnetic Stimulation for Mental Illness
Boston, Massachusetts
Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Pregnancy, Cluster B Disorders, PTSD, Others
Must Not Be Taking:Ketamine, Esketamine, ECT
180 Participants Needed
Nerve Stimulation for Weight Loss and Diabetes
Gainesville, Florida
The goal of the study to understand the effects of weight loss and improvements in diabetes following bariatric surgery on brain function and thinking. This study will also examine whether non-invasive transcutaneous vagal nerve stimulation (tVNS) intervention initiated 30 days post-surgery improves brain function and thinking. The study does NOT cover any costs associated with bariatric surgery.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:20 - 75
Key Eligibility Criteria
Disqualifiers:Neurological, Psychiatric, Cancer, Others
120 Participants Needed
tDCS for Cognitive Impairment
Gainesville, Florida
The current study is a mechanistic study to evaluate working memory gains from application of transcranial direct current stimulation (tDCS) in older adults with mild cognitive impairments (MCI) compared to cognitively healthy control
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:60 - 95
Key Eligibility Criteria
Disqualifiers:Neurological Disorders, Seizures, Psychiatric Disorders, Cancer, Others
Must Not Be Taking:GABAergic, Glutamatergic, Calcium Blockers, Sodium Blockers
110 Participants Needed
Why Other Patients Applied
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
Near-infrared Light Therapy for Brain Aging
Oklahoma City, Oklahoma
The goal of this pilot clinical trial is to test whether transcranial photobiomodulation (tPBM), a non-invasive brain stimulation technique using near-infrared light, can improve brain blood flow regulation (neurovascular coupling) and cognitive function in older adults.
The main questions it aims to answer are:
* Does tPBM enhance neurovascular coupling responses during memory and finger tapping tasks?
* Are these improvements linked to better cognitive performance and lower levels of brain inflammation and oxidative stress?
Researchers will compare an active tPBM treatment arm to a sham treatment arm to see if tPBM leads to measurable improvements in brain activity and cognitive function compared to no active stimulation.
Participants will:
* Receive either active tPBM or sham stimulation sessions for 4 weeks, every other day using a portable intervention device.
* Complete questionnaires and an iPAD-based cognitive testing protocol
* Complete memory and motor tasks while their brain activity is measured using non-invasive techniques: simultaneous functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG), transcranial doppler (TCD) flowmetry.
* Retinal vessel reactivity will be measured during flickering light stimulus using a special camera (dynamic vessel analysis, DVA).
* Provide blood samples to test for biomarkers of inflammation, oxidative stress and brain cell damage.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:21 - 85
Key Eligibility Criteria
Disqualifiers:CNS Disease, Stroke, Major Psychiatric, Others
Must Not Be Taking:Dietary Supplements
30 Participants Needed
Fluconazole for Vascular Response in Healthy Subjects
Norman, Oklahoma
Most cardiometabolic diseases are characterized by increased muscle sympathetic nerve activity (MSNA) during rest and exercise which contributes to poor health outcomes. In healthy humans during muscle contraction, there is a blunting of skeletal muscle vascular responsiveness to increases in MSNA. However, the exact mechanisms involved are unknown although, best evidence suggests that the mechanism is endothelium derived, but nitric oxide (NO) and prostaglandin (PG) independent. Endothelium-derived hyperpolarizing factor (EDHF) is a NO and PG independent vasodilator in both cerebral and skeletal muscle circulations, however, it is unknown if EDHF contributes to vascular responsiveness during elevated MSNA. The application of lower body negative pressure (LBNP) is a safe and non-invasive manipulation that can be used to increase MSNA causing vasoconstriction in humans. Therefore, the purpose of this experiment is to determine if acute inhibition of EDHF alters central and peripheral vascular responses to LBNP at rest and during dynamic exercise. Thereby, providing evidence by which EDHF contributes to vascular control in healthy humans and identify it's potential as a therapeutic target for cardiometabolic diseases that are characterized by elevated MSNA
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 30
Key Eligibility Criteria
Disqualifiers:Smoking, Hypertension, Cardiometabolic Diseases, Others
Must Not Be Taking:Amiodarone, Sulphaphenazole, S-warfarin, Others
30 Participants Needed
Intensive Blood Pressure Management for Dementia
Dallas, Texas
The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:60 - 85
Key Eligibility Criteria
Disqualifiers:Stroke, Dementia, Depression, Heart Disease, Diabetes, Others
Must Be Taking:Antihypertensives
180 Participants Needed
XO Genius Beverage for Cognitive and Physiological Health
Arlington, Texas
The primary objectives of this application are to 1) investigate the effect of increased daily consumption of the Keto5 XOGenius beverage on outcomes associated with elevated risk for various neurocognitive and pathophysiological conditions/diseases. And 2) to investigate the effect of daily consumption of the Keto5 XOGenius beverage on the following variables: waist circumference, body weight, and body mass index (BMI).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 50
Key Eligibility Criteria
Disqualifiers:Food Allergies, Diabetes, IBS, Others
Must Not Be Taking:Cardiovascular, Metabolic, Stimulants
40 Participants Needed
Peanuts for Brain and Heart Health
Arlington, Texas
The overall research objective of this proposal is to determine the impact of increased daily peanut consumption on indices of neurocognitive and physiological health in BL individuals
No Placebo Group
Trial Details
Trial Status:Recruiting
Age:18 - 50
Key Eligibility Criteria
Disqualifiers:Peanut Allergy, Hypertensive Crisis, Pregnant, Others
60 Participants Needed
Goode Health Beverage for Overall Health
Arlington, Texas
The overall research objective of this proposal is to determine the acute and chronic impact of daily supplementation of a Good Health beverage on indices of physiological and neurocognitive health.
Trial Details
Trial Status:Recruiting
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:Food Allergy, Pregnant, Breastfeeding, Others
40 Participants Needed
Transcranial Photobiomodulation for Cognitive Decline
Arlington, Texas
The overall research objective of this proposal is to determine the acute and chronic impact of transcranial photobiomodulation on indices of cerebral vascular health and neurocognitive function.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Brain Injuries, Epilepsy, Pacemakers, Others
100 Participants Needed
Resistance Exercise for Glioblastoma
Halifax, Nova Scotia
This trial tests a personalized exercise routine for brain cancer patients to help them build muscle and improve their ability to do daily activities. The goal is to counteract muscle weakness caused by long-term steroid use during cancer treatment.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Cardiac, Pulmonary, Cognitive, Seizures, Others
24 Participants Needed
BCI-Controlled Devices for Motor Disorders
Austin, Texas
Injuries affecting the central nervous system may disrupt the cortical pathways to muscles causing loss of motor control. Nevertheless, the brain still exhibits sensorimotor rhythms (SMRs) during movement intents or motor imagery (MI), which is the mental rehearsal of the kinesthetics of a movement without actually performing it. Brain-computer interfaces (BCIs) can decode SMRs to control assistive devices and promote functional recovery. Despite rapid advancements in non-invasive BCI systems based on EEG, two persistent challenges remain: First, the instability of SMR patterns due to the non-stationarity of neural signals, which may significantly degrade BCI performance over days and hamper the effectiveness of BCI-based rehabilitation. Second, differentiating MI patterns corresponding to fine hand movements of the same limb is still difficult due to the low spatial resolution of EEG. To address the first challenge, subjects usually learn to elicit reliable SMR and improve BCI control through longitudinal training, so a fundamental question is how to accelerate subject training building upon the SMR neurophysiology. In this study, the investigators hypothesize that conditioning the brain with transcutaneous electrical spinal stimulation, which reportedly induces cortical inhibition, would constrain the neural dynamics and promote focal and strong SMR modulations in subsequent MI-based BCI training sessions - leading to accelerated BCI training. To address the second challenge, the investigators hypothesize that neuromuscular electrical stimulation (NMES) applied contingent to the voluntary activation of the primary motor cortex through MI can help differentiate patterns of activity associated with different hand movements of the same limb by consistently recruiting the separate neural pathways associated with each of the movements within a closed-loop BCI setup. The investigators study the neuroplastic changes associated with training with the two stimulation modalities.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Cognitive Deficits, Metabolic Disorders, Others
Must Not Be Taking:CNS Affecting
100 Participants Needed
Semaglutide for Obesity
Aurora, Colorado
Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Age:12 - 45
Key Eligibility Criteria
Disqualifiers:Type 2 Diabetes, Anorexia, Bulimia, Others
Must Not Be Taking:Antipsychotics
120 Participants Needed
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do Brain Function clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Brain Function clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Brain Function trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Brain Function is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Brain Function medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Brain Function clinical trials?
Most recently, we added Whole-Body Hyperthermia for Postpartum Depression, Semaglutide for Obesity and Yogurt Smoothies for Brain and Gut Health to the Power online platform.
Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.